The holistic perspective of chronic obstructive pulmonary disease: Doubt some more

Therapeutic Advances in Chronic Disease

Volumn 1, Issue 2, 2010, Pages 37-41

  Morjaria, Jaymin B ^a   Polosa, Riccardo ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; PLACEBO; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; EDITORIAL; HOLISTIC CARE; HUMAN; INFECTION; INFLAMMATION; MORTALITY; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION;

EID: 79952915430     PISSN: 20406223     EISSN: None     Source Type: Journal    
DOI: 10.1177/2040622310373959     Document Type: Editorial

References (33)

1. Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E. and Connett, J.E. ( 2005) The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial. Ann Intern Med 142: 233-239.
2. Boyle, P., Gray, N., Henningfield, J., Seffrin, J. and Zatonski, W. ( 2004) Tobacco and Public Health: Science and Policy. Oxford University Press: Oxford.
3. Cacciola, R.R., Guarino, F. and Polosa, R. ( 2007) Relevance of Endothelial-Haemostatic Dysfunction in Cigarette Smoking. Curr Med Chem 14: 1887-1892.
4. Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W. et al. (2007) Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 356: 775-789.
5. Casella, G., Caponnetto, P. and Polosa, R. ( 2010) Therapeutic Advances in the Treatment of Nicotine Addiction: Present and Future. Ther Adv Chronic Dis (In Press).
6. de Torres, J.P., Pinto-Plata, V., Casanova, C., Mullerova, H., Cordoba-Lanus, E., Muros de Fuentes, M. et al. (2008) C-Reactive Protein Levels and Survival in Patients with Moderate to Very Severe Copd. Chest 133: 1336-1343.
7. Dickstein, K., Cohen-Solal, A., Filippatos, G., Mcmurray, J.J., Ponikowski, P., Poole-Wilson, P.A. et al. (2008) Esc Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association of the Esc (Hfa) and Endorsed by the European Society of Intensive Care Medicine (Esicm). Eur Heart J 29: 2388-2442.
8. Fiore, M.C.C.R.J., Baker, T.B., Bailey, W.C., Benowitz, N.L., Curry, S.J. et al. (2008) Treating Tobacco Use and Dependence: 2008 Update. Us Dept of Health and Human Services, Public Health and Human Service. May.
9. Franciosi, L.G., Page, C.P., Celli, B.R., Cazzola, M., Walker, M.J., Danhof, M. et al. (2006) Markers of Disease Severity in Chronic Obstructive Pulmonary Disease. Pulm Pharmacol Ther 19: 189-199.
10. Gan, W.Q., Man, S.F., Senthilselvan, A. and Sin, D.D. ( 2004) Association between Chronic Obstructive Pulmonary Disease and Systemic Inflammation: A Systematic Review and a Meta-Analysis. Thorax 59: 574-580.
11. Hughes, J.R., Keely, J. and Naud, S. ( 2004) Shape of the Relapse Curve and Long-Term Abstinence among Untreated Smokers. Addiction 99: 29-38.
12. Komajda, M., Follath, F., Swedberg, K., Cleland, J., Aguilar, J.C., Cohen-Solal, A. et al. (2003) The Euroheart Failure Survey Programme-a Survey on the Quality of Care among Patients with Heart Failure in Europe. Part 2: Treatment. Eur Heart J 24: 464-474.
13. Kony, S., Zureik, M., Driss, F., Neukirch, C., Leynaert, B. and Neukirch, F. ( 2004) Association of Bronchial Hyperresponsiveness and Lung Function with C-Reactive Protein (Crp): A Population Based Study. Thorax 59: 892-896.
14. Lightwood, J.M. and Glantz, S.A. ( 1997) Short-Term Economic and Health Benefits of Smoking Cessation: Myocardial Infarction and Stroke. Circulation 96: 1089-1096.
15. Lowe, G.D. and Pepys, M.B. ( 2006) C-Reactive Protein and Cardiovascular Disease: Weighing the Evidence. Curr Atheroscler Rep 8: 421-428.
16. Lowe, G.D., Yarnell, J.W., Rumley, A., Bainton, D. and Sweetnam, P.M. ( 2001) C-Reactive Protein, Fibrin D-Dimer, and Incident Ischemic Heart Disease in the Speedwell Study: Are Inflammation and Fibrin Turnover Linked in Pathogenesis? Arterioscler Thromb Vasc Biol 21: 603-610.
17. Man, S.F., Connett, J.E., Anthonisen, N.R., Wise, R.A., Tashkin, D.P. and Sin, D.D. ( 2006) C-Reactive Protein and Mortality in Mild to Moderate Chronic Obstructive Pulmonary Disease. Thorax 61: 849-853.
18. Morjaria, J.B., Malerba, M. and Polosa, R. (2010) Biologic and Pharmacologic Therapies in Clinical Development for the Inflammatory Response in COPD. Drug Discov Today 15(9-10): 396-405.
19. Mortensen, E.M., Copeland, L.A., Pugh, M.J., Restrepo, M.I., de Molina, R.M., Nakashima, B. et al. (2009) Impact of Statins and Ace Inhibitors on Mortality after Copd Exacerbations. Respir Res 10: 45.
20. Pepys, M.B. and Hirschfield, G.M. ( 2003) C-Reactive Protein: A Critical Update. J Clin Invest 111: 1805-1812.
21. Ridker, P.M. ( 2001) High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. Circulation 103: 1813-1818.
22. Ridker, P.M. ( 2004) Inflammation in Atherothrombosis: How to Use High-Sensitivity C-Reactive Protein (Hscrp) in Clinical Practice. Am Heart Hosp J 2: 4-9.
23. Sinden, N.J. and Stockley, R.A. ( 2010) Chronic Obstructive Pulmonary Disease: An Update of Treatment Related to Frequently Associated Comorbidities. Ther Adv Chronic Dis: 43-57.
24. Soyseth, V., Brekke, P.H., Smith, P. and Omland, T. ( 2007) Statin Use Is Associated with Reduced Mortality in Copd. Eur Respir J 29: 279-283.
25. Takabatake, N., Nakamura, H., Abe, S., Inoue, S., Hino, T., Saito, H. et al. (2000) The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor-Alpha System in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 161: 1179-1184.
26. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S. et al. (2008) A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 359: 1543-1554.
27. US Department of Health and Human Services ( 1990). The Health Benefits of Smoking Cessation (Dhhs Publication No. (Cdc) 90-8516). USA; US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
28. van der Vaart, H., Postma, D.S., Timens, W. and Ten Hacken, N.H. ( 2004) Acute Effects of Cigarette Smoke on Inflammation and Oxidative Stress: A Review. Thorax 59: 713-721.
29. Wannamethee, S.G., Lowe, G.D., Shaper, A.G., Rumley, A., Lennon, L. and Whincup, P.H. ( 2005) Associations between Cigarette Smoking, Pipe / Cigar Smoking, and Smoking Cessation, and Haemostatic and Inflammatory Markers for Cardiovascular Disease. Eur Heart J 26: 1765-1773.
30. Willemse, B.W., Ten Hacken, N.H., Rutgers, B., Lesman-Leegte, I.G., Postma, D.S. and Timens, W. ( 2005) Effect of 1-Year Smoking Cessation on Airway Inflammation in Copd and Asymptomatic Smokers. Eur Respir J 26: 835-845.
31. Wilson, K., Gibson, N., Willan, A. and Cook, D. ( 2000) Effect of Smoking Cessation on Mortality after Myocardial Infarction: Meta-Analysis of Cohort Studies. Arch Intern Med 160: 939-944.
32. Yanbaeva, D.G., Dentener, M.A., Creutzberg, E.C., Wesseling, G. and Wouters, E.F. ( 2007) Systemic Effects of Smoking. Chest 131: 1557-1566.
33. Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F. et al. (2004) Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the Interheart Study): Case-Control Study. Lancet 364: 937-952.